Accession Number:

AD1103142

Title:

Mesenchymal Stem Cell Therapy for Traumatic Brain Injury

Descriptive Note:

Technical Report,15 Mar 2019,14 Mar 2020

Corporate Author:

U.S. Army Medical Research Fort Detrick United States

Personal Author(s):

Report Date:

2020-04-01

Pagination or Media Count:

27.0

Abstract:

Traumatic brain injury TBI is a significant cause of death and disability in both military and civilian populations. Cell therapy with mesenchymal stem cells MSCs or other progenitors shows promise for TBI treatment and other types of brain injury, but further work is needed to define the optimal MSC products to minimize risk and maximize benefit. MSC products are not all equivalent in safety and potency, and different MSCs are likely to have different efficacy. Here we implement in vitro testing to evaluate both safety and potency of different MSCs, which will ultimately be validated using an animal model for rat TBI. Maximal tolerated dose of MSCs will be determined in both uninjured and severely injured rats, and the distribution and retention of labeled cells in vivo following IV administration will be determined. Finally, rats will be subjected to moderate TBI and the effects of MSC administration will be evaluated.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE